During the research period, 55 patients received the HeartMate II between Oct. 5, 2005, and Jan. 1, 2010, as part of either bridge to transplantation or destination therapy trials. Patients were separated into two age groups: 70 years of age or younger (30 patients) and older than 70 years of age (25 patients). Pre-operatively, all patients were classified as having severe heart failure, showing symptoms of cardiac insufficiency at rest (New York Heart Association Class IV). The research team compared outcome measures between the two groups including survival, length of hospital stay, adverse events and quality of life.
The survival rate between the two groups was not statistically different. For patients older than 70, the survival rate was 97 percent at one month, 75 percent at one year and 70 percent at two years. For patients 70 and younger, the rate was 96 percent at one month, 72 percent at one year and 65 percent at two years.
The average length of hospital stay for the older group was 24 days, which was similar to length of stay for the younger group (23 days). The researchers found no differences in the incidence of adverse events between the two groups, and quality of life and functional status improved significantly in both groups.
Co-authors of the study at Sharp Memorial include Marcia Stahovich, RN; Suzanne Chillcott, BSN; Sam Baradarian, MD; Joseph Chammas, MD; Brian Jaski, MD; Peter Hoagland, MD and Walter Dembitsky, MD.
About Sharp Memorial Hospital
Sharp Memorial Hospital, which first opened its doors in 1955, is part of Sharp HealthCare, San Diego's most comprehensive health care delivery system, recognized for clinical
|SOURCE Sharp HealthCare|
Copyright©2010 PR Newswire.
All rights reserved